Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma.
Adult
Aged
Antigens, Neoplasm
/ genetics
Biomarkers, Tumor
/ genetics
Brain Neoplasms
/ genetics
Exome
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Glioma
/ genetics
High-Throughput Nucleotide Sequencing
Humans
Immune Evasion
/ immunology
Longitudinal Studies
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Middle Aged
Mutation
Neoplasm Recurrence, Local
/ genetics
Prognosis
Retrospective Studies
Survival Rate
Young Adult
Journal
Cancer immunology research
ISSN: 2326-6074
Titre abrégé: Cancer Immunol Res
Pays: United States
ID NLM: 101614637
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
10
09
2018
revised:
23
01
2019
accepted:
07
05
2019
pubmed:
16
5
2019
medline:
10
9
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
Immune-based therapies have shown limited efficacy in glioma thus far. This might be at least in part due to insufficient numbers of neoantigens, thought to be targets of immune attack. In addition, we hypothesized that dynamic genetic and epigenetic tumor evolution in gliomas might also affect the mutation/neoantigen landscape and contribute to treatment resistance through immune evasion. Here, we investigated changes in the neoantigen landscape and immunologic features during glioma progression using exome and RNA-seq of paired primary and recurrent tumor samples obtained from 25 WHO grade II-IV glioma patients (glioblastoma, IDH-wild-type,
Identifiants
pubmed: 31088845
pii: 2326-6066.CIR-18-0599
doi: 10.1158/2326-6066.CIR-18-0599
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1148-1161Informations de copyright
©2019 American Association for Cancer Research.